-
公开(公告)号：US10941181B2
公开(公告)日：2021-03-09
申请号：US15226161
申请日：2016-08-02
发明人： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC分类号： A61K38/00 , C07K7/06 , A61K39/00 , C07K7/08 , A61K35/17 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10709735B2
公开(公告)日：2020-07-14
申请号：US16507437
申请日：2019-07-10
发明人： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC分类号： A61K35/17 , A61K39/00 , C07K14/47 , C07K14/495 , C07K14/725 , C07K19/00 , C12N5/0783 , C07K7/06 , C07K7/08 , C07K16/40 , C12N9/02 , C12N9/10 , A61K38/00
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10479818B2
公开(公告)日：2019-11-19
申请号：US16444693
申请日：2019-06-18
发明人： Toni Weinschenk , Steffen Walter , Jens Fritsche , Colette Song , Harpreet Singh
摘要： A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US10420800B2
公开(公告)日：2019-09-24
申请号：US16196402
申请日：2018-11-20
发明人： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC分类号： A61K35/17 , C07K14/47 , C07K14/495 , C12N9/02 , A61K39/00 , C07K7/06 , C07K7/08 , C07K19/00 , C07K14/725 , C07K16/40 , C12N5/0783 , C12N9/10 , A61K38/00
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US10357540B2
公开(公告)日：2019-07-23
申请号：US15639506
申请日：2017-06-30
摘要： A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.
-
公开(公告)号：US10046037B2
公开(公告)日：2018-08-14
申请号：US15226081
申请日：2016-08-02
发明人： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC分类号： A61K35/17 , A61K39/00 , C07K7/06 , C07K7/08 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783 , A61K38/00
CPC分类号： C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US09993540B2
公开(公告)日：2018-06-12
申请号：US15638806
申请日：2017-06-30
发明人： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
CPC分类号： C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
摘要： A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has brain cancer. A method of treating a patient who has brain cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the brain cancer.
-
公开(公告)号：US09943579B2
公开(公告)日：2018-04-17
申请号：US15639058
申请日：2017-06-30
发明人： Toni Weinschenk , Steffen Walter , Jens Fritsche , Colette Song , Harpreet Singh
IPC分类号： A61K39/00 , A61K45/06 , C12N5/0783 , C12N9/64 , C07K14/725
CPC分类号： A61K39/0011 , A61K38/1709 , A61K45/06 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/7051 , C12N5/0638 , C12N9/6491 , C12N2502/11 , C12Y304/24065
摘要： A method of treating a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma. A method of treating a patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the NSCLC, lung cancer, gastric cancer, and/or glioblastoma.
-
公开(公告)号：US20170326217A1
公开(公告)日：2017-11-16
申请号：US15638806
申请日：2017-06-30
发明人： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC分类号： A61K39/00
CPC分类号： C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
摘要： A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has brain cancer. A method of treating a patient who has brain cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the brain cancer.
-
公开(公告)号：US09717774B2
公开(公告)日：2017-08-01
申请号：US14615539
申请日：2015-02-06
CPC分类号： A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.069 秒)
